Yumurtalik kanserinde TNF-β gen polimorfizmin rolü
Bu tez size mi ait?
Bu kayıt toplu arşivden geldi. Sizinse profilinize bağlayın.
Özet (EN)
This study explored the relationship between ovarian cancer (OC) risk in Turkish women and polymorphisms in TNF-β (+252A>G), which are known to play a critical role in malignancy development. The study included 47 cases and 45 controls and used RT-PCR for genotyping analysis. Statistical analysis was conducted to compare significant differences between the groups. The outcomes showed that the control group had an AA genotype at 64.4% (29 out of 45), an AG genotype at 35.5% (16 out of 45), and a GG genotype at 0% (0 out of 40). In the ovarian cancer patient group, the AA genotype was at 53.1% (25 out of 47), the AG genotype at 29.7% (14 out of 47), and the GG genotype at 8.5% (4 out of 47). However, no significance was observed when comparing the groups, with a p-value of 0.802. more extensive studies with larger population scales are necessary to determine the exact association. Key words: Ovarian cancer, TNF-β, polymorphism
Yazar
Shıya Husseın Ibrahım Ibrahım
Bu Yayına Nasıl Atıf Yapılır
Shıya Husseın Ibrahım Ibrahım (Master Thesis). Yumurtalik kanserinde TNF-β gen polimorfizmin rolü, 2023, Yeditepe University.
Anahtar Kelimeler
Lisans
Tüm Hakları Saklıdır
Bu eser belirtilen lisans koşulları altında paylaşılmaktadır.
Yeditepe University tezlerinden daha fazlası
- Studies on cyclodextrin complexation of a poorly water soluble anti-hyperlipidemic drug, tablet formulation and characterization(2021)
- Washington ambassadors in Turkish-US relations (1927-1960)(2023)
- Metamorphosis of female voices: A study of the violation of women in Greek and Roman mythology and feminist rewritings reclaiming the narrative(2022)
- Knowledge distillation with foundation models for image segmentation(2023)
- The relationship between machiavelism, grandiose and vulnerable narcissism, and loneliness among white collar workers(2023)
- Evaluation of drug-drug interaction checkers along clinically relevant adverse drug events in oncology and hematology pediatric patients(2023)